Allogene Therapeutics, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Allogene Therapeutics, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue		0	0	114	0.16	0.1	0.02	0
Research and development	152	145	193	220	256	243	192	150
General and administrative	41	57.5	65.3	74.1	79.3	71.7	65.2	56.8
Operating expenses	193	202	258	294	336	328	273	209
Operating income	-193	-202	-258	-180	-336	-328	-273	-209
Interest expense	3.36	0	0			0	0.18	1.08
Other non-operating income	-18.8	17.1	-58.1	-1.86	-4.88	0.47	16.1	18.4
Pre-tax income	-212	-185	-250	-257		-327	-257	-191
Income tax	-0.12	-0.33	0	0	0	0	0.44	0
Net income	-212	-185	-316	-182	-340	-327	-258	-191
EBITDA	-192	-197	-251	-170	-321	-314	-260	-197
EPS, basic	-9.24	-2.31	-2.63	-1.34	-2.38	-2.09	-1.32	-0.87
EPS, diluted	-9.24	-2.31	-2.63	-1.34	-2.38	-2.09	-1.32	-0.87
Shares, basic (weighted)	22.9	79.9	120	136	143	157	195	221
Shares, diluted (weighted)	22.9	79.9	120	136	143	157	195	221
Dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Balance sheet

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	92.4	175	183	173	61.9	83.2	75.2	51.7
Short-term investments	367	355	645	284	455	366	217	199
Other current assets	8.6	14	17.2	14	11.5	10.4	10.9	7.54
Total current assets	468	545	845	471	529	459	303	258
Property, plant and equipment	8.6	56.4	119	123	113	99.5	86.1	72.8
Lease right-of-use assets	33	44.5	41.3	58	83.6	63.7	45.2	39.9
Intangible assets	0.75	0.15	0
Long-term investments	262	58.3	204	352	59.2	0	80.7	8.04
Other non-current assets	0.24	4.62	5.17	5.82	9.56	6.6	2.33	3.62
Total assets	774	718	1,228	1,051	822	643	549	416
Accounts payable	12.3	9.25	10.4	10.3	13.9	5.9	5.39	4.27
Accrued liabilities				16.1	17.9	12.7	12.1	10.2
Deferred revenue		0	39	0.16	0.1	0.09
Total current liabilities	29.5	33.1	94.3	47.9	53.7	37.1	35.5	32.5
Lease liabilities	34.5	51.3	50.8	69.9	95.1	88.3	83.2	75
Other non-current liabilities	6.78	4.35	3.08	7.79	5.85	5.18	7.76	15.8
Total liabilities	70.7	88.8	148	126	155	131	127	123
Paid-in capital	914	1,024	1,726	1,822	1,912	2,075	2,242	2,303
Retained earnings	-212	-396	-713	-895	-1,235	-1,562	-1,820	-2,011
Other comprehensive income	0.31	1.15	0.27	-2.57	-9.93	-0.96	-0.09	0.27
Shareholders' equity	703	629	1,013	925	667	512	422	293
Total equity	703	629	1,013	925	667	512	422	293
Total liabilities and equity	774	718	1,228	1,051	822	643	549	416
Shares outstanding	96.1	98.3	140	143	144	169	212	229

Cash flow statement

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-212	-185	-316	-182	-340	-327	-258	-191
Depreciation and amortization	1	4.6	7.4	10.5	14.3	14.2	13.6	12.4
Stock-based compensation	18.6	46.1	65.3	80.8	83.6	66	51.7	37.6
Deferred income tax						0	0.44	0
Change in payables	8.8	-0.99	0.62	-0.77	4.87	-7.5	-0.5	-1.23
Cash from operations	-44.7	-137	-115	-185	-221	-238	-200	-149
Capital expenditures	-3.23	-50.8	-66	-21.4	-5.19	-1.52	-0.69	-0.39
Purchases of investments	-649	-253	-1,038	-526	-248	-439	-361	-138
Sales and maturities of investments				728	359	598	432	234
Cash from investing	-633	164	-505	164	106	163	75.7	95.6
Stock issued	344	0	596	0	0	91.1
Cash from financing	771	59	634	12	2.95	95.7	117	30.2
Net change in cash	93.7	85.7	13.4	-9.19	-111	21.3	-7.94	-23.5
Free cash flow	-47.9	-188	-181	-206	-226	-239	-201	-150

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.65 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Return on equity (ROE)	-37.9%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-30.1%	Net income / average total assets.
Return on invested capital (ROIC)	-35.8%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-100.0%	Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	-30.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-24.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-22.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-24.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-20.3%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-19.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	13.2%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	15.5%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	12.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	10.7x	Current assets / current liabilities.
Quick ratio	10.5x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	10.5x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	20.7%	Total liabilities / total assets.
Interest coverage	-139x	Operating income / interest expense.
Working capital	$308.3M	Current assets - current liabilities.
Tangible book value	$436.2M	Shareholders' equity - goodwill - intangible assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.50	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share	-$0.31	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.31	Cash from operations / diluted weighted shares.
Book value per share	$1.26	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.26	Tangible book value / shares outstanding.
Cash per share	$0.96	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$570.1M	Share price x shares outstanding.
Enterprise value	$237.5M	Market cap + total debt - cash - short-term investments.
P/B	1.31x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	1.31x	Market cap / tangible book value, when positive.
FCF yield	-18.0%	Free cash flow / market cap.
Earnings yield	-29.0%	Net income / market cap (the inverse of P/E).

What was Allogene Therapeutics, Inc.'s revenue in fiscal 2025?

Allogene Therapeutics, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.

Was Allogene Therapeutics, Inc. profitable in fiscal 2025?

No. It reported a net loss of $190.9M.

How much free cash flow did Allogene Therapeutics, Inc. generate in fiscal 2025?

Cash from operations of $149.2M minus capital expenditures of $386.0K left free cash flow of -$149.6M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Allogene Therapeutics, Inc.